← Back to Search

7T MRI Scan for Brain Cancer

N/A
Waitlist Available
Led By Jason Johnson
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult patients with newly identified and untreated central nervous system glioma or metastasis of at least 5 mm or greater in size
History of central nervous system glioma or metastasis treated with surgery, radiation, chemotherapy, or immunotherapy with new or increasing signal on MR imaging that is suspicious for progressive disease (treatment failure)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if 7T MRI can detect central nervous system tumors better than standard MRI. It could help find & diagnose tumors and measure patient response to treatment.

Who is the study for?
This trial is for adults with new or suspected recurrent central nervous system tumors, including gliomas and metastases. Participants may have had previous treatments like surgery or chemotherapy. They must have a tumor of at least 5mm that's visible on an MRI scan and not be pregnant, claustrophobic, allergic to contrast agents used in MRIs, or have renal failure.
What is being tested?
The study is testing the effectiveness of a high-resolution 7T MRI scan compared to standard MRI scans in detecting and monitoring brain tumors. It aims to determine if the newer technology provides clearer images for better diagnosis and treatment evaluation.
What are the potential side effects?
There are generally no direct side effects from undergoing a 7T MRI scan itself; however, some individuals might experience discomfort due to lying still for long periods or anxiety within the confined space of the scanner.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a newly diagnosed brain tumor or cancer spread to the brain that is at least 5 mm.
Select...
I had brain cancer or cancer spread to my brain treated, but recent scans suggest it might be getting worse.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Contrast-to-noise ratio (CNR)
Secondary study objectives
Conspicuity of each imaging modality to differentiate radiation necrosis from progressive disease
Other study objectives
Functional (f)MRI paradigms
Patient satisfaction

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (7T MRI)Experimental Treatment2 Interventions
Patients undergo 7T MRI over 60 minutes.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,071 Previous Clinical Trials
1,803,130 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,945 Previous Clinical Trials
41,024,624 Total Patients Enrolled
Jason JohnsonPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
Max WintermarkPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

7 Tesla Magnetic Resonance Imaging Clinical Trial Eligibility Overview. Trial Name: NCT04539574 — N/A
Brain Tumor Research Study Groups: Diagnostic (7T MRI)
Brain Tumor Clinical Trial 2023: 7 Tesla Magnetic Resonance Imaging Highlights & Side Effects. Trial Name: NCT04539574 — N/A
7 Tesla Magnetic Resonance Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT04539574 — N/A
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top